NASDAQ · CLGN
CollPlant Biotechnologies financials
$3.79−2.07%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $515.0K | $11.0M | $299.0K | $15.6M | $6.1M | $2.3M | $5.0M |
| Gross profit | $1.5M | -$1.1M | $9.0M | -$101.0K | $13.6M | $3.1M | $439.0K | $3.4M |
| Gross margin | 64.8% | −215.5% | 81.8% | −33.8% | 87.2% | 51.1% | 18.9% | 66.9% |
| Operating income | -$11.5M | -$17.3M | -$7.5M | -$17.1M | $65.0K | -$5.6M | -$7.6M | -$4.2M |
| Net income | -$11.5M | -$16.6M | -$7.0M | -$16.9M | $237.0K | -$5.8M | -$11.2M | -$6.2M |
| Net margin | −484.6% | −3225.0% | −64.0% | −5660.5% | 1.5% | −94.1% | −481.6% | −124.6% |
| Diluted EPS | $-9.40 | $-14.50 | $-6.20 | $-15.30 | $0.20 | $-8.40 | $-22.30 | $-14.30 |
| EBITDA | -$10.6M | -$16.2M | -$6.4M | -$16.0M | $838.0K | -$4.9M | -$7.1M | -$3.9M |
| Operating cash flow | -$9.4M | -$14.1M | -$2.8M | -$13.7M | $2.5M | -$4.5M | -$5.7M | -$1.2M |
| Free cash flow | -$9.4M | -$14.6M | -$3.7M | -$15.0M | $1.1M | -$4.9M | -$7.2M | -$2.0M |
| Diluted shares | 1.2M | 1.1M | 1.1M | 1.1M | 1.2M | 0.7M | 0.5M | 0.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.6M | $11.9M | $26.7M | $29.7M | $13.1M | $3.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $10.8M | $18.7M | $34.1M | $37.8M | $51.2M | $10.8M |
| Total liabilities | $4.7M | $5.2M | $5.8M | $5.5M | $6.1M | $6.4M |
| Shareholders' equity | $6.1M | $13.5M | $28.3M | $32.3M | $45.1M | $4.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology